Research Papers

25 of 215 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Chemotherapy for Metastatic Gastric Cancer: Does Age Matter? A Single-Center, Retrospective, Real-World Study.
Liao PW; Cheng SB; Chou CW; Lin HC; Lin CH; Chen TC; Hsu CY; Jerry Teng CL; Shih YH.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Design and Development of an Intelligent System for Predicting 5-Year Survival in Gastric Cancer.
Afrash MR; Shanbehzadeh M; Kazemi-Arpanahi H.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Roundabout Guidance Receptor 1 Is an Emerging Prognostic Biomarker for Nasopharyngeal Carcinoma.
Lee SW; Yang CC; Lai HY; Tsai HH; Yeh CF; Kuo YH; Kang NW; Chen TJ; Chang SL.
Clin Med Insights Oncol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor.
Wang Y; Liu A; Xu T; Yin J; Chen W.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Overexpression of LIMA1 Indicates Poor Prognosis and Promotes Epithelial-Mesenchymal Transition in Head and Neck Squamo…
Ma W; Liao Y; Gao Z; Zhu W; Liu J; She W.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With <i>EGFR</i> Mutation-Positive …
Liu R; Zhou J; Ling X.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of…
Xiu W; Guo X; Yu M; Li Y; Xu Y; Zhu J; Luo J.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Diagnostic Ability of Volatile Organic Compounds in Digestive Cancer: A Systematic Review With Meta-Analysis.
Yang H; Mou Y; Hu B.
Clin Med Insights Oncol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, …
Uchimiak K; Badowska-Kozakiewicz AM; Sobiborowicz-Sadowska A; Deptała A.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Use of Computed Tomography-Guided Percutaneous Biopsy of Invasive Non-Mucinous Lung Adenocarcinoma to Predict the Degre…
Liu D; Chen L; Wang X; Lin Y; Gu J.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Radiomics Features of Different Sizes of Medullary Thyroid Carcinoma (MTC) and Papillary Thyroid Carcinoma (PTC) Tumors…
Zhao L; Ma B; Ma B.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Comparison of Gene Expression Profiles of Signet Ring Cell Carcinoma and Poorly Cohesive Carcinoma in Early Gastric Can…
Yeo MK; Kang SH; Jeong KB; Lee HS; Jeon HJ; Eun HS; Lee ES; Moon HS; Kim SH; Sung JK; Lee BS; Jeong HY.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Clinicopathological Features of Papillary Renal Cell Carcinoma With Venous Tumor Thrombus: Case Series from a Large Chi…
Liu Z; Ge L; Zhao X; Lu M; Aili A; Li Y; Zhu G; Hong P; Tian X; Wang S; Zhang H; Liu C; Ding Z; Zhang S; Ma L.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Body Mass Index and Diabetes Mellitus May Predict Poorer Overall Survival of Oral Squamous Cell Carcinoma Patients: A R…
Adnan Y; Ali SMA; Awan MS; Zahid N; Awan MO; Afzal Kayani H; Farooqui HA.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer.
Stokke K; Sandvei MS; Grønberg BH; Slaaen M; Killingberg KT; Halvorsen TO.
Clin Med Insights Oncol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR…
Lu X; Wang J; Wang C; Liang J; Zhou Z; Chen D; Feng Q; Xiao Z; Hui Z; Lu J; Zhang T; Liu W; Wang J; Wang X; Deng L; Zhai Y; Bi N; Wang L.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Whole-Brain Radiotherapy Combined With Anlotinib for Multiple Brain Metastases From Non-small Cell Lung Cancer Without …
Liu J; Xu J; Ye W; Zhong W; Zhang X; Mao J; Wu D.
Clin Med Insights Oncol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Complement 4 Aids in the Prediction of Newly Diagnosed Multiple Myeloma Outcome in Patients.
Zhang L; Ling X; Li F; Yang T; Shi K; Zhao S; Yu L; Li Z; He H.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Radiomics in Nasopharyngeal Carcinoma.
Duan W; Xiong B; Tian T; Zou X; He Z; Zhang L.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Radiation-Induced Fibrosis in Patients with Head and Neck Cancer: A Review of Pathogenesis and Clinical Outcomes.
Ramia P; Bodgi L; Mahmoud D; Mohammad MA; Youssef B; Kopek N; Al-Shamsi H; Dagher M; Abu-Gheida I.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
<i>PIK3CA</i> Mutations in Diffuse Gliomas: An Update on Molecular Stratification, Prognosis, Recurrence, and Aggressiv…
Brito C; Tomás A; Azevedo A; Esteves S; Mafra M; Roque L; Pojo M.
Clin Med Insights Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives…
Cheng K; Wang Y; Zhou Y; Xia R; Tang L; Liu J.
Clin Med Insights Oncol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Nomogram Incorporating Contrast-Enhanced Ultrasonography Predicting Time to the Development of Castration-Resistant Pro…
Zhao YX; Yao GL; Sun J; Wang XL; Wang Y; Cai QQ; Kang HL; Gu LP; Yu JS; Li WM; Zhang B; Wang J; Mei JJ; Jiang Y.
Clin Med Insights Oncol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer.
Rhea LP; Aragon-Ching JB.
Clin Med Insights Oncol (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects.
Li T; Liu T; Zhu W; Xie S; Zhao Z; Feng B; Guo H; Yang R.
Clin Med Insights Oncol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared